Jubilant Pharmova’s subsidiary -- Jubilant Cadista Pharmaceuticals Inc., USA, (Jubilant Cadista) has received Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the US Food and Drug Administration (USFDA) for its solid oral formulations facility at Salisbury, Maryland, USA (Facility) with respect to the inspection conducted by the said regulatory agency in January 2025.
With the receipt of the EIR from the USFDA, the inspection stands successfully closed. Going forward, the said Facility is not expected to manufacture any products as it has closed manufacturing operations.
Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.
